Success and continuous growth of the ERS clinical research collaborations
- PMID: 34795029
- DOI: 10.1183/13993003.02527-2021
Success and continuous growth of the ERS clinical research collaborations
Conflict of interest statement
Conflict of interest: M. van den Berge declares research grants (paid to institution) from GlaxoSmithKline, Roche, Genentech, Sanofi, AstraZeneca and Novartis, in the 36 months prior to manuscript submission. Conflict of interest: C. Genton is an employee of the European Respiratory Society. Conflict of interest: E. Heuvelin is an employee of the European Respiratory Society. Conflict of interest: A.K. Simonds has nothing to disclose. Conflict of interest: M. Humbert has nothing to disclose. Conflict of interest: A. Nyberg has nothing to disclose. Conflict of interest: R. Gosens declares research grants (paid to institution) from Aquilo, Sanofi-Genzyme and Boehringer Ingelheim, in the 36 months prior to manuscript submission. Conflict of interest: L. Donnelly has nothing to disclose. Conflict of interest: O. Fulton has nothing to disclose. Conflict of interest: M. Wilkens has nothing to disclose. Conflict of interest: N. Roche declares research grants (paid to institution) from GlaxoSmithKline, Boehringer Ingelheim, Pfizer and Novartis; consulting fees from Boehringer Ingelheim, Novartis, Pfizer, Teva, GlaxoSmithKline, AstraZeneca, Chiesi, Sanofi and Zambon; and honoraria for speaking or writing from Boehringer Ingelheim, Novartis, Pfizer, Teva, GlaxoSmithKline, AstraZeneca, Chiesi, Sanofi and Zambon, all in the 30 months prior to manuscript submission. Conflict of interest: C. Brightling has nothing to disclose.
Publication types
LinkOut - more resources
Full Text Sources